Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 13, 2017High and durable response rate in disease without any FDA-approved therapies
-
Dec 11, 2017* First FDA-approved follow-on mealtime insulin
-
Dec 7, 2017Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments
-
Dec 4, 2017First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec
-
Nov 30, 2017Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec
-
Oct 31, 2017First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline
-
Oct 16, 2017- Late-breaking oral abstract presented at the World Congress of Gastroenterology -
-
Oct 11, 2017- Understand AD: A Day in the Life, Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy and Understanding of this Unrelenting, Chronic Disease -
-
Oct 5, 2017- Praluent continues to be available to patients in the U.S. -
-
Sep 28, 2017- First targeted biologic in the European Union to receive marketing authorization for use in atopic dermatitis -
-
Sep 20, 2017- In preclinical studies, trispecific antibodies show exceptional potency against diverse HIV viruses -
-
Sep 20, 2017- Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo -
-
Sep 16, 2017- Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress -
-
Sep 12, 2017-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --
-
Sep 11, 2017- Investigational dupilumab reduced severe asthma attacks and improved lung function -
-
Aug 28, 2017- An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio -